Analyse produit facultative
Avec votre autorisation, nous utilisons une analyse limitée et respectueuse de la vie privée pour comprendre les parcours de recherche utiles. Nous n’utilisons ni traceurs publicitaires ni enregistrement de session. Vous pouvez modifier ce choix dans les préférences. Consultez la Politique de confidentialité.
Colgate-Palmolive Company's published Reduce conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $68.6B | |
|---|---|---|
| Revenue (ttm) | 21B | |
| Net income (ttm) | 2B | |
| EPS (ttm) | $2.53 | |
| Shares out | 797.2M | |
| P/E (trailing) | 36.1x | |
| P/E (forward) | 21.0x | |
| Dividend | $2.12 (2.32%) | |
| Volume | 2,983,423 | |
| Beta | 0.32 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $17.42B | $17.97B | $19.46B | $20.10B | $20.38B | +4.0% |
| Gross profit | $10.38B | $10.25B | $11.33B | $12.16B | $12.25B | +4.2% |
| Operating income | $3.33B | $2.89B | $3.98B | $4.27B | $3.31B | -0.2% |
| Net income | $2.17B | $1.79B | $2.30B | $2.89B | $2.13B | -0.4% |
| EPS (diluted) | $2.55 | $2.13 | $2.77 | $3.51 | $2.63 | +0.8% |
| EBITDA | $3.76B | $3.37B | $4.25B | $4.85B | $3.96B | +1.3% |
| R&D | $307.0M | $320.0M | $343.0M | $355.0M | $366.0M | +4.5% |
| SG&A | $6.41B | $6.57B | $7.15B | $7.73B | $7.90B | +5.4% |
Recent company headlines from major financial publishers.
In the base outcome, yielding $74.00 with an estimated probability of 60.0% and an expected return of -14.0%, Colgate-Palmolive delivers steady organic growth across its core franchises. Mass merchant channel inventory stabilizes, and gross profit gains are balanced by necessary advertising reinvestment to maintain defensive market share. However, because $86.06 trades above Fair value of $74.00, the expected return profile remains negative at -14.0%, validating a Reduce recommendation.
In the bull outcome, projected at $101.51 with an estimated probability of 15.0% and an expected return of 18.0%, Colgate-Palmolive accelerates international oral care premiumization while Hill's Pet Nutrition expands veterinary market share globally. Gross margin gains outpace cost inflation, allowing operating margins to surpass historical peaks even after funding strong commercial marketing. This scenario would be disconfirmed if retail partners resist premium shelf allocation or if emerging market currency devaluations erode reported sales gains.
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 6.2% | $84.2 | $87.5 | $91.4 | $95.8 | $101 |
| 6.7% | $76.2 | $78.8 | $81.6 | $84.8 | $88.5 |
| 7.2% | $69.9 | $71.8 | $74.0 | $76.4 | $79.1 |
| 7.7% | $64.7 | $66.2 | $67.9 | $69.8 | $71.9 |
| 8.2% | $60.3 | $61.5 | $62.9 | $64.4 | $66.0 |
Upcoming earnings date and setup when available.
La notation portée par l'édition de recherche publiée chaque mois. Une notation compare le cours à la date d'analyse à la juste valeur ; elle n'indique pas si l'appréciation s'est révélée juste.
| Année | janv. | févr. | mars | avr. | mai | juin | juil. | août | sept. | oct. | nov. | déc. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |